A Study to Evaluate Effects of KN056 in Healthy Participants

NCT05385575 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: KN056 (0.1mg)
DRUG: KN056 (0.3mg)
DRUG: KN056 (1.0mg)
DRUG: KN056 (3.0mg)
DRUG: KN056 (6.0mg)
DRUG: KN056 (12.0mg)
DRUG: KN056 (18.0mg)

Sponsor

Suzhou Alphamab Co., Ltd.

Collaborators

[object Object]